# Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients

> **NCT02592980** · PHASE4 · UNKNOWN · sponsor: **University of Sao Paulo General Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **GENETIC:** Pharmacogenetic anticoagulation
- **DRUG:** Traditional anticoagulation

## Key facts

- **NCT ID:** NCT02592980
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2019-11
- **Final completion:** 2020-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02592980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02592980, "Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02592980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*